Pain is an unpleasant sensory and emotional sensation associated with tissue damage or described in terms of such damage. Pain of different localization is one of the most common symptoms in modern clinical practice and one of the most common reasons for seeking medical care at the outpatient stage.
One of the most promising and effective pathogenetic means of protection of peripheral pain receptors (nociceptors) are nonsteroidal anti-inflammatory drugs (NSAIDs). Every day, more than 30 million people in the world take NSAIDs, more than 300 million a year, and only a third of them take nonsteroidal anti-inflammatory drugs as prescribed by a doctor. However, patients taking various drugs today are considered as possible etiological and provoking factors in the development of a number of diseases of various organs and systems. All this determines the importance of selecting the optimal drug from the group of nonsteroidal anti-inflammatory drugs both from the standpoint of effectiveness and from the standpoint of safety in real clinical practice and including at the outpatient stage of providing medical care to the patient.
One of the latest developments in this direction is dexibuprofen, the right-handed active isomer of ibuprofen, which according to numerous studies can be used as a symptomatic therapy of pain of mild to moderate intensity of various origins: toothache, back pain, joints, muscles, rheumatic pain, dysmenorrhea, and feel free to recommend it to a wide range of patients, as it has the optimal combination of efficacy and safety profile.